{
    "nct_id": "NCT03728673",
    "official_title": "A Pilot Study Utilizing Escitalopram to Address Cognitive Dysfunction in Glioma Patients",
    "inclusion_criteria": "* Patient with pathologically proven diagnosis of Grade IV glioma\n* Patients planning to receive chemotherapy and/or radiation for newly diagnosed disease\n* Performance status ECOG 0-2 or equivalent\n* Patients must be age ≥19 years\n* Life expectancy greater than 6 months\n* Written informed consent to participate in the study.\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Hemifield defects (as this obscures visual field necessary to participate in all tests)\n* Inability to undergo MRI\n* Severe renal impairment defined as GFR<30 mL/minute\n* Screen positive for depression or anxiety\n* Already taking an anti-depressant (SSRI or NSRI)\n* Have problems tolerating past treatment with SSRI or NSRIs\n* Females of childbearing potential must have a negative urine pregnancy test at the study enrollment.\n* Female patients must be either postmenopausal, free from menses for ≥2 years, surgically sterilized, or willing to use two adequate barrier forms of contraception",
    "miscellaneous_criteria": ""
}